Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$728K, compared with $1.75M a year earlier. Trailing-twelve-month change in working capital was -$11.6M.
Context
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near -$728K or moves back toward the trailing-twelve-month quarterly average of -$2.9M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (9.12M) USD
- Year-over-year change
- +44.8%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.12M) | +44.8% |
| FY2024 | 2024-12-31 | (16.54M) | -382.1% |
| FY2023 | 2023-12-31 | 5.86M | -55.8% |
| FY2022 | 2022-12-31 | 13.25M | -20.2% |
| FY2021 | 2021-12-31 | 16.61M | — |
Change in Working Capital vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 change in working capital of $11.6M is the 5th largest of the 11 companies compared; the peer median is $4.17M.
- Its year-over-year change of -384.3% is the 8th highest of 11, against a peer median of -83.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.2M | -455.5% | — | 58.4% | |
| LTM Mar 2026 | $28.81M | -17.6% | — | 63.9% | |
| LTM Mar 2026 | $17.87M | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | $16.57M | -13682.0% | — | — | |
| LTM Mar 2026 | $11.6M | -384.3% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $4.39M | -464.7% | -52.1% | — |
| LTM Mar 2026 | $3.95M | +22.3% | -67.6% | — | |
| LTM Mar 2026 | $2.88M | -73.3% | -61.2% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $1.93M | -48.2% | — | 27.0% |
| LTM Mar 2026 | $1.73M | -162.8% | -44.0% | 172.9% | |
| LTM Mar 2026 | $301.74K | -94.4% | +140.1% | — | |
| Peer median (excluding ZNTL) | $4.17M | -83.9% | -48.1% | 58.4% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (166.09M) | (237.11M) | (292.19M) | (165.87M) | (137.06M) |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| Deferred Income Tax | (2.51M) | (769K) | (853K) | 0 | 0 |
| Stock-Based Compensation | 35.74M | 46.84M | 54.82M | 67.27M | 20.72M |
| Change in Working Capital | 16.61M | 13.25M | 5.86M | (16.54M) | (9.12M) |
| Accounts Receivables | 413K | 0 | 0 | (5M) | 5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13.96M | 15.53M | 10.92M | (18.02M) | (17.32M) |
| Other Working Capital | 2.23M | (2.28M) | (5.06M) | 6.48M | 3.19M |
| Other Non-Cash Items | (38.38M) | 12.61M | 23.15M | (57.01M) | (526K) |
| Operating Cash Flow | (154.09M) | (163.75M) | (207.82M) | (170.86M) | (125.25M) |
| Capital Expenditures | (6.11M) | (2.55M) | (583K) | (221K) | 0 |
| Acquisitions (Net) | (14.32M) | 111.63K | 0 | 65K | 0 |
| Purchases of Investments | (363.51M) | (533.16M) | (549.18M) | (127.96M) | (139.49M) |
| Sales of Investments | 365.82M | 421.53M | 505.31M | 304.68M | 270.41M |
| Other Investing Activities | 0 | (111.63K) | 0 | 0 | 698K |
| Investing Cash Flow | (18.12M) | (114.18M) | (44.46M) | 176.56M | 131.62M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 179.67M | 261.04M | 237.3M | 349K | (4.28M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.15M) | 0 | 0 | (241K) | 0 |
| Financing Cash Flow | 178.52M | 261.04M | 237.3M | 108K | (4.28M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 6.31M | (16.89M) | (14.98M) | 5.81M | 2.09M |
| Free Cash Flow | (160.2M) | (166.3M) | (208.41M) | (171.08M) | (125.25M) |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.